Metamizol +pharma

Metamizole sodium, the active ingredient in Metamizol +pharma, is a pyrazolone analgesic presented as an oral formulation for oral use. It is employed to manage moderate to severe pain, high fever, and visceral colic in adult patients. The product is marketed across the European Union and is available only by prescription.

GNH USA supplies Metamizol +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and offers reliable global distribution for this prescription‑only analgesic.

Metamizol +pharma is used to treat conditions involving pain and fever through inhibition of prostaglandin synthesis.

- Moderate to severe pain: provides analgesia for acute or postoperative pain. - High fever: reduces elevated body temperature when other antipyretics are insufficient. - Visceral colic: alleviates spasm‑related abdominal pain such as renal colic.

Metamizole sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Skin rash: mild erythematous reaction. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction of white blood cells. - Anaphylactic reaction: life‑threatening hypersensitivity. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing Metamizol +pharma, clinicians should observe several safety measures to minimize risks.

- Monitor blood counts: regular CBC testing is recommended due to risk of agranulocytosis. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Use caution in renal impairment: dose adjustment may be required. - Limit concurrent myelosuppressive therapy: increased risk of blood dyscrasias. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metamizol +pharma can interact with other medicines, influencing safety and efficacy.

Major Interactions (Avoid): - Concurrent use with other bone‑marrow suppressants: may potentiate agranulocytosis. - Combination with other NSAIDs or COX inhibitors: increased risk of gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - Antihypertensive agents: additive hypotensive effect. - Diuretics: may affect renal clearance.